Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04196283 · ClinicalTrials.gov registry record · Phase 1
A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
A Phase 1 study of Advanced Solid Tumors Cancer, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 20
- Study locations
NCT04196283 is a Phase 1 study of Advanced Solid Tumors Cancer that has completed, run by AbbVie. The registered enrollment target is 30 participants, below the 351-participant average among 9 other Advanced Solid Tumors Cancer trials with a reported enrollment target (91% lower). The trial reports 20 study locations across 18 states.
The verdict
NCT04196283, a Phase 1 study of Advanced Solid Tumors Cancer, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK) of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and ABBV-181 in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Conditions Studied
Interventions
- DRUG Nab-paclitaxel
- DRUG ABBV-181
- DRUG ABBV-368
- DRUG Tilsotolimod
Study Locations (20)
Other
- Charite Universitaetsklinikum Berlin - Campus Benjamin Franklin /ID# 214197 - Berlin
- Rambam Health Care Campus /ID# 215231 - Haifa
- Gastroenterology Institute, Division of Medicine /ID# 215862 - Jerusalem
Illinois
- The University of Chicago Medical Center /ID# 217196 - Chicago
Kentucky
- Norton Cancer Institute /ID# 216179 - Louisville
Michigan
- Barbara Ann Karmanos Cancer In /ID# 214050 - Detroit
Nebraska
- Nebraska Methodist Hospital /ID# 215786 - Omaha
New Jersey
- Atlantic Health System /ID# 216159 - Morristown
New York
- Roswell Park Comprehensive Cancer Center /ID# 215882 - Buffalo
Tennessee
- Vanderbilt Ingram Cancer Center /ID# 214040 - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2020-01-22 |
| Est. Completion | 2022-10-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04196283
The ClinicalTrials.gov registry entry for NCT04196283 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 351-participant average among 9 other Advanced Solid Tumors Cancer trials with a reported enrollment target (91% lower). The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Advanced Solid Tumors Cancer appearing as the primary indexed condition, and to 4 interventions - of which Nab-paclitaxel is the first listed.
NCT04196283 reports 20 study locations spanning 18 distinct geographic areas - top geographies include Other, Illinois, Kentucky.
Frequently Asked Questions
What is clinical trial NCT04196283 about?
NCT04196283 is a clinical study titled "A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma". The main objective of this study is to assess safety, tolerability, and pharmacokinetics (PK) of ABBV-368 plus tilsotolimod; ABBV-368 plus tilsotolimod and nab-paclitaxel; and ABBV-368 plus tilsotolimod, nab-paclitaxel, and ABBV-181 in participants with recurrent/metastatic (R/M) head and neck squam...
What is the current status of trial NCT04196283?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2020-01-22. Estimated completion is 2022-10-27.
What conditions does trial NCT04196283 study?
This clinical trial studies the following conditions: Advanced Solid Tumors Cancer.
What interventions are being tested in trial NCT04196283?
The interventions under investigation include: Nab-paclitaxel (DRUG), ABBV-181 (DRUG), ABBV-368 (DRUG), Tilsotolimod (DRUG).
Who is sponsoring clinical trial NCT04196283?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04196283 being conducted?
This trial has 20 study locations across Illinois, Kentucky, Michigan, Nebraska, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumors Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer
RECRUITING · Phase 1
-
A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors.
RECRUITING · Phase 1
-
ORB-021 In Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
-
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.